180 related articles for article (PubMed ID: 34244670)
1. Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomes.
Sivaprasad S; Ghanchi F; Kelly SP; Kotagiri A; Talks J; Scanlon P; McGoey H; Nolan A; Saddiq M; Napier J;
Eye (Lond); 2022 Jan; 36(1):64-71. PubMed ID: 34244670
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes.
Sivaprasad S; Ghanchi F; Kelly SP; Kotagiri A; Talks J; Scanlon P; McGoey H; Nolan A; Saddiq M; Napier J
Eye (Lond); 2023 Sep; 37(13):2753-2760. PubMed ID: 36941402
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes.
Sivaprasad S; Ghanchi F; Kelly SP; Kotagiri A; Talks J; Scanlon P; McGoey H; Nolan A; Saddiq M; Napier J; Morgan-Warren P
Eye (Lond); 2023 Aug; 37(12):2527-2534. PubMed ID: 36653595
[TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study.
Korobelnik JF; Daien V; Faure C; Tadayoni R; Giocanti-Auregan A; Dot C; Kodjikian L; Massin P
Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):521-528. PubMed ID: 31894377
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
[TBL] [Abstract][Full Text] [Related]
8. Aflibercept for Diabetic Macular Edema in Real-Life Practice in GREece: Three-Year Outcomes of the ADMIRE Study.
Chatziralli I; Agapitou C; Dimitriou E; Kapsis P; Kazantzis D; Machairoudia G; Georgiadis O; Theodossiadis G; Theodossiadis P
Semin Ophthalmol; 2024 Jan; 39(1):96-101. PubMed ID: 37539994
[TBL] [Abstract][Full Text] [Related]
9. Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT.
Lois N; Campbell C; Waugh N; Azuara-Blanco A; Maredza M; Mistry H; McAuley D; Acharya N; Aslam TM; Bailey C; Chong V; Downey L; Eleftheriadis H; Fatum S; George S; Ghanchi F; Groppe M; Hamilton R; Menon G; Saad A; Sivaprasad S; Shiew M; Steel DH; Talks JS; Doherty P; McDowell C; Clarke M
Health Technol Assess; 2022 Dec; 26(50):1-86. PubMed ID: 36541393
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.
Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM
Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal Aflibercept versus Ranibizumab for Diabetic Macular Edema in a Taiwanese Health Service Setting.
Tsai MJ; Cheng CK
Semin Ophthalmol; 2021 Apr; 36(3):132-138. PubMed ID: 33661709
[No Abstract] [Full Text] [Related]
12. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
13. Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study.
Wachtlin J; Eter N; Hasanbasic Z; Keramas G; Rech C; Sachs H; Schilling H; Wiedemann P; Framme C
Graefes Arch Clin Exp Ophthalmol; 2021 Mar; 259(3):601-611. PubMed ID: 32789651
[TBL] [Abstract][Full Text] [Related]
14. THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Creuzot-Garcher C; Arnold JJ; Mehta H; Duran MA; Bougamha W; Carreño E; Viola F; Squirrell D; Barthelmes D; Gillies M
Retina; 2022 Jun; 42(6):1085-1094. PubMed ID: 35174799
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
[TBL] [Abstract][Full Text] [Related]
16. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.
Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D
Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092
[TBL] [Abstract][Full Text] [Related]
17. An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data.
Muston D; Korobelnik JF; Reason T; Hawkins N; Chatzitheofilou I; Ryan F; Kaiser PK
BMC Ophthalmol; 2018 Dec; 18(1):340. PubMed ID: 30591022
[TBL] [Abstract][Full Text] [Related]
18. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes.
Sugimoto M; Handa C; Hirano K; Sunaya T; Kondo M
Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3489-3498. PubMed ID: 35652946
[TBL] [Abstract][Full Text] [Related]
20. Functional and anatomic results of up to 24 months aflibercept treatment for diabetic macular edema in real-life setting.
Tsapardoni FN; Makri OE; Lagogiannis AP; Tsekouras IK; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
Hell J Nucl Med; 2019; 22 Suppl 2():47-54. PubMed ID: 31802045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
